Takeaways: CDA-AMC’s conditional reimbursement recommendation for Yorvipath moves the therapy closer to public funding in Canada for adults with chronic hypoparathyroidism who are not ...
Takeaways: Knight Therapeutics’ Canadian launch of WYNZORA strengthens its dermatology portfolio and marks the commercialization of a product it inherited through the Paladin acquisition. The launch a...
Takeaways: CDA‑AMC’s positive, conditional reimbursement recommendation for Nucala (mepolizumab) in adults with COPD and raised blood eosinophils who remain uncontrolled on ICS/LABA/LAMA triple therap...
Takeaways: The expanded approval of Lynkuet for AET‑related VMS gives Canadian oncologists and breast cancer patients the first non‑hormonal, evidence‑based option specifically indicated for...
Takeaways: Light AI’s Health Canada Class II license for QuickScan Strep A clears the way to commercialize an AI‑based clinical decision support tool that analyzes digital throat images to h...
Takeaways: Slenyto gives Canadian clinicians a prescription, extended‑release melatonin specifically studied for children and teens (ages 2 to <18) with autism spectrum disorder and/or Smith‑Mageni...
Takeaways: Bracco’s VueJect is the first dedicated injector for cardiac ultrasound contrast, so it can make echocardiograms with Lumason/SonoVue more consistent, less dependent on who is doing the inj...
Takeaways: Health Canada’s approval of Fasenra for hypereosinophilic syndrome (HES) gives Canadian patients a much‑needed, evidence‑backed option that can cut flare‑ups and improve fatigue, potentiall...
Takeaways: By combining a TSXV listing with a Health Canada-accepted ANDS for a domestically made generic Ozempic, Vimy is positioning itself to compete in a fast-growing, high-value GLP-1 marke...
Takeaways: The main market signal is strategic rather than commercial: Health Canada’s clearance, alongside PHAC’s collaboration with Moderna, helps de-risk the company’s mRNA infectious-disease...
